Trial Condition(s):
Dermatitis, Atopic
Efficacy and tolerance of once-daily methylprednisolone aceponate cream in comparison with twice-daily betamethasone valerate in patients with atopic dermatitis
Bayer Identifier:
Trial_89171
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
A multicenter, open, parallel group comparative study comparing the
therapeutic efficacy and tolerance of methylprednisolone aceponate
(MPA) 0.1% cream once-daily and twice-daily application of
betamethasone valerate (BMV) 0.1% cream in the treatment of
patients of both sexes suffering from atopic dermatitis.
Inclusion Criteria
: - Atopic dermatitis, necessity of a therapy with a potent topical corticosteroid on a cream base. - Age ≥ 14 years
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status |
|---|
Trial Design
Controlled, multicenter trial on efficacy and tolerance of a once-daily application of methylprednisolone aceponate (MPA) cream in comparison with a twice-daily application of betamethasone valerate (BMV) in patients with atopic dermatitis
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
N/A
Blinding:
N/A
Assignment:
Parallel Assignment
Trial Arms:
2
Primary Outcome
- Physician's overall assessment of therapeutic effect at the end of the treatment periodTimeframe:
Secondary Outcome
- Objective symptoms (erythema, scaling, lichenification, prurigo, rhagades, and excoriation) assessed as severe, mild or absentTimeframe:
- Subjective complaints (itching, burning, pain) assessed as severe, mild or absentTimeframe:
- Overall skin condition of diseased areas (graded as very good, good, moderate or bad)Timeframe:
Additional Information
Copyright © Bayer
Powered by
